CHMP recommends Krystexxa (Savient Pharma) for treatment of Gout - 21-Oct-2012
On 18 October 2012, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Krystexxa, 8 mg/ml, concentrate from Savient Pharma, for solution for infusion intended for the treatment of severe debilitating chronic tophaceous Gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.
Related News
NICE does not recommend Krystexxa (Savient Pharma) for treatment of severe Gout
CHMP recommends Krystexxa (Savient Pharma) for treatment of Gout
FDA requires more data for Arcalyst (Regeneron) for Gout Flares treatment
Positive data in study of Krystexxa (Savient Pharma) in patients with Gout
Positive Phase III data for Krystexxa (Savient Pharma) in Gout patients with chronic Kidney Disease
FDA Advisory Committee rejects Arcalyst(Regeneron) for treatment of Gout Flares
Arcalyst (Regeneron) is filed at FDA for Gout Flares
FDA approves Nymalize (Arbor Pharmaceuticals) for Sub Arachnoid Haemorrhage
Related Rheumatology Information
Rheumatology Clinical Guidelines
Clinical practice guideline for the assessment and prevention of falls in older people
NICEOsteoarthritis: National clinical guideline for care and management in adults
NICERheumatology Clinical Trials
A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid Arthritis
Clinicaltrials.gov 11 April 2013A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
Clinicaltrials.gov 10 April 2013Rheumatology Medical Journal Abstracts
Which Patients Are Most Likely to Benefit From Total Joint Arthroplasty?
Arthritis & Rheumatism 23 April 2013Variants in RUNX3 Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis
Arthritis & Rheumatism 23 April 2013Rheumatology Medical Apps
Miniatlas Osteoporosis
£1.49
Rheumatoid Arthritis
£6.19
Related Rheumatology Drugs
- CALCIUM-SANDOZ SYRUP
- PREMPAK-C
- NABUMETONE TABLETS 500MG
- ACTONEL ONCE A WEEK
- NAPRATEC OP
- ACTONEL COMBI
- TRISEQUENS® FILM-COATED TABLETS
- ORENCIA 125 MG SOLUTION FOR INJECTION (PRE-FILLED SYRINGE)
- NUVELLE CONTINUOUS
- FOSAMAX TABLETS
- ETOPAN XL 600 MG TABLETS
- FABLYN
- ACTONEL 30MG FILM-COATED TABLETS
- FASTURTEC
- ACLASTA 5 MG SOLUTION FOR INFUSION
- BONVIVA 150MG FILM-COATED TABLETS
- ESTRING
- CIMZIA 200 MG SOLUTION FOR INJECTION
- METOJECT 50 MG/ML SOLUTION FOR INJECTION
- CELEBREX 200 MG CAPSULE
- PROLIA
- CALCICHEW-D3 500 MG/400IU CAPLETS
- VAGIFEM 25 MICROGRAMS FILM-COATED TABLETS
- EVOREL SEQUI
- VIRORMONE INJECTION
- VIMOVO 500 MG/20 MG MODIFIED-RELEASE TABLETS
- EVOREL CONTI
- LEFLUNOMIDE WINTHROP 20MG TABLETS
- ENBREL 25 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
- NAPROXEN 500 MG TABLETS
- ALENDRONIC ACID 70MG TABLETS
- HUMIRA PRE-FILLED PEN, PRE-FILLED SYRINGE AND VIAL
- PROTELOS
- NAPROXEN TABLETS 250MG
- LODOTRA® 1 MG, 2 MG AND 5 MG MODIFIED-RELEASE TABLETS
- ESTRADOT TRANSDERMAL PATCH
- ACTONEL 5 MG FILM-COATED TABLETS
- DIDRONEL PMO
- IBANDRONIC ACID 150MG FILM-COATED TABLETS
- KALCIPOS-D 500 MG/ 800 IU CHEWABLE TABLETS
- EVOREL 25, 50, 75 & 100 PATCHES
- EVISTA 60MG FILM-COATED TABLETS
Advert for Healthcare Professionals only